Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 60

1.

ADAM8/MS2/CD156, an emerging drug target in the treatment of inflammatory and invasive pathologies.

Koller G, Schlomann U, Golfi P, Ferdous T, Naus S, Bartsch JW.

Curr Pharm Des. 2009;15(20):2272-81. Review.

PMID:
19601829
[PubMed - indexed for MEDLINE]
2.

ADAM10 as a therapeutic target for cancer and inflammation.

Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML.

Curr Pharm Des. 2009;15(20):2288-99. Review.

PMID:
19601831
[PubMed - indexed for MEDLINE]
3.

Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8.

Naus S, Reipschläger S, Wildeboer D, Lichtenthaler SF, Mitterreiter S, Guan Z, Moss ML, Bartsch JW.

Biol Chem. 2006 Mar;387(3):337-46.

PMID:
16542157
[PubMed - indexed for MEDLINE]
4.

ADAM8 in allergy.

Matsuno O, Kumamoto T, Higuchi Y.

Inflamm Allergy Drug Targets. 2008 Jun;7(2):108-12. Review.

PMID:
18691140
[PubMed - indexed for MEDLINE]
5.

ADAM17 as a therapeutic target in multiple diseases.

Arribas J, Esselens C.

Curr Pharm Des. 2009;15(20):2319-35. Review.

PMID:
19601834
[PubMed - indexed for MEDLINE]
6.

The therapeutic potential of ADAM15.

Lucas N, Najy AJ, Day ML.

Curr Pharm Des. 2009;15(20):2311-8. Review.

PMID:
19601833
[PubMed - indexed for MEDLINE]
7.

Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death.

Naus S, Richter M, Wildeboer D, Moss M, Schachner M, Bartsch JW.

J Biol Chem. 2004 Apr 16;279(16):16083-90. Epub 2004 Feb 4.

PMID:
14761956
[PubMed - indexed for MEDLINE]
Free Article
8.

Role of ADAM8 in experimental asthma.

Matsuno O, Miyazaki E, Nureki S, Ueno T, Kumamoto T, Higuchi Y.

Immunol Lett. 2006 Jan 15;102(1):67-73. Epub 2005 Aug 2.

PMID:
16154205
[PubMed - indexed for MEDLINE]
9.

The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.

Dehmel T, Janke A, Hartung HP, Goebel HH, Wiendl H, Kieseier BC.

Neurobiol Dis. 2007 Mar;25(3):665-74. Epub 2007 Jan 3.

PMID:
17207628
[PubMed - indexed for MEDLINE]
10.

Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23.

Fourie AM, Coles F, Moreno V, Karlsson L.

J Biol Chem. 2003 Aug 15;278(33):30469-77. Epub 2003 May 30.

PMID:
12777399
[PubMed - indexed for MEDLINE]
Free Article
11.

The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs.

Amour A, Knight CG, English WR, Webster A, Slocombe PM, Knäuper V, Docherty AJ, Becherer JD, Blobel CP, Murphy G.

FEBS Lett. 2002 Jul 31;524(1-3):154-8.

PMID:
12135759
[PubMed - indexed for MEDLINE]
Free Article
12.

Upregulation of ADAM8 in the airways of mice with allergic bronchial asthma.

Chiba Y, Onoda S, Hattori Y, Maitani Y, Sakai H, Misawa M.

Lung. 2009 May-Jun;187(3):179-85. doi: 10.1007/s00408-009-9145-7. Epub 2009 Apr 17.

PMID:
19373511
[PubMed - indexed for MEDLINE]
13.

ADAM9 as a potential target molecule in cancer.

Peduto L.

Curr Pharm Des. 2009;15(20):2282-7. Review.

PMID:
19601830
[PubMed - indexed for MEDLINE]
14.

Autoactivation of human ADAM8: a novel pre-processing step is required for catalytic activity.

Hall T, Leone JW, Wiese JF, Griggs DW, Pegg LE, Pauley AM, Tomasselli AG, Zack MD.

Biosci Rep. 2009 Aug;29(4):217-28. doi: 10.1042/BSR20080145.

PMID:
18811590
[PubMed - indexed for MEDLINE]
Free Article
15.

ADAMs in cancer cell proliferation and progression.

Mochizuki S, Okada Y.

Cancer Sci. 2007 May;98(5):621-8. Epub 2007 Mar 9. Review.

PMID:
17355265
[PubMed - indexed for MEDLINE]
16.

The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.

Pruessmeyer J, Ludwig A.

Semin Cell Dev Biol. 2009 Apr;20(2):164-74. doi: 10.1016/j.semcdb.2008.09.005. Epub 2008 Sep 18. Review.

PMID:
18951988
[PubMed - indexed for MEDLINE]
17.

ADAM10 is a principal 'sheddase' of the low-affinity immunoglobulin E receptor CD23.

Weskamp G, Ford JW, Sturgill J, Martin S, Docherty AJ, Swendeman S, Broadway N, Hartmann D, Saftig P, Umland S, Sehara-Fujisawa A, Black RA, Ludwig A, Becherer JD, Conrad DH, Blobel CP.

Nat Immunol. 2006 Dec;7(12):1293-8. Epub 2006 Oct 29.

PMID:
17072319
[PubMed - indexed for MEDLINE]
18.

ADAM8: a new therapeutic target for asthma.

Knolle MD, Owen CA.

Expert Opin Ther Targets. 2009 May;13(5):523-40. doi: 10.1517/14728220902889788 . Review.

PMID:
19397475
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

ADAM proteins - therapeutic potential in cancer.

Lu X, Lu D, Scully M, Kakkar V.

Curr Cancer Drug Targets. 2008 Dec;8(8):720-32. Review.

PMID:
19075595
[PubMed - indexed for MEDLINE]
20.

ADAM8 substrate specificity: influence of pH on pre-processing and proteoglycan degradation.

Hall T, Pegg LE, Pauley AM, Fischer HD, Tomasselli AG, Zack MD.

Arch Biochem Biophys. 2009 Nov;491(1-2):106-11. doi: 10.1016/j.abb.2009.09.005. Epub 2009 Sep 18.

PMID:
19766586
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk